Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Salestools Logo

Salestools

Der #1 KI-Agent für Vertriebsteams und Go-to-Market-Teams. Verkaufen Sie mehr, schneller, mit weniger Aufwand.

Produkt

  • KI-Vertriebsagenten
  • Intent-Daten
  • Technologiedaten
  • Besucher-Tracking
  • Co-Pilot
  • Social Selling

Lösungen

  • Kundenservice
  • E-Commerce
  • SaaS
  • Enterprise
  • Kleinunternehmen

Ressourcen

  • Der Report
  • Dokumentation
  • API-Referenz
  • Hilfecenter
  • Blog
  • Fallstudien
  • Webinare

Unternehmen

  • Über uns
  • Karriere
  • Presse
  • Kontakt
  • Partner

Unsere Standorte

  • New York, HQ
  • Bukarest, KI-Forschungslabor
  • Zug, Schweiz

© 2025 Salestools. Alle Rechte vorbehalten.

Datenbedingungen & SicherheitDatenschutzerklärungNutzungsbedingungen
Alle Systeme betriebsbereit
Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Back to The Report
Biotech

Sana Biotechnology

Sana Biotechnology raises $700M IPO at $4.2B valuation

$700M
Total Raised
IPO
Latest Round
2018
Founded
400+
Employees
188 East Blaine Street, Seattle, WA 98102
Updated February 4, 2024
1 min read

Quick Facts

Valuation
$4.2B
Latest Round Size
$700M
Latest Round Date
February 2024

Sana Biotechnology: IPO Funding Round

Sana Biotechnology has successfully raised $700M in IPO funding, reaching a valuation of $4.2B.

Company Overview

Cell and gene therapy platform

Funding Details

The IPO round was led by Flagship Pioneering, with participation from ARCH Venture Partners, F-Prime Capital, Baillie Gifford.

Company Information

  • Headquarters: 188 East Blaine Street, Seattle, WA 98102
  • Founded: 2018
  • Employees: 400+
  • Category: Biotech

Investment

Sana Biotechnology plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Flagship Pioneering: Verified investor in IPO
  • ARCH Venture Partners: Verified investor in IPO
  • F-Prime Capital: Verified investor in IPO
  • Baillie Gifford: Verified investor in IPO

Key Investors

Flagship Pioneering
Lead Investor
Verified investor in IPO
ARCH Venture Partners
Investor
Verified investor in IPO
F-Prime Capital
Investor
Verified investor in IPO
Baillie Gifford
Investor
Verified investor in IPO

Topics

verified(3079)real-funding(3079)sana-biotechnologybiotechipo188-east-blaine-street

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M